Jason A. Keyes

Filings by Jason A. Keyes span 3 companies, the busiest being Equillium, Inc., BlossomHill Therapeutics, Inc. and Sesen Bio, Inc. In total, 19 filings cover trades dated from 26 May 2021 to 10 August 2026.

In open-market terms, that means 1 purchase worth €9,691 on one side and 12 sales worth €229k on the other. The net balance comes to €219k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 6 share grants. 2026 to date brings 1 purchase and no sales.

Most recently, on 10 August 2026, the filings show an open-market purchase worth €9,691 in BlossomHill Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.